MAP®
... a Revolution in Protein Nutrition

MAP optimizes the Body Protein Synthesis without burdening the liver and kidneys with nitrogen waste or glucose. Therefore it’s ideal in clinical nutrition for:

- Preventing tumor cachexia
- Ketogenic or hyperketogenic diet in epilepsy or cancer
- Diabetic nutrition
- Other Clinical nutrition
  - Rheumatic-arthritis-inflammatory diseases
  - Hepatic encephalopathy
  - Geriatric nutrition, allergies

Nutritional Value of MAP® compared to other proteins

- NNU = Net Nitrogen Utilization and it’s the percentage of amino acids following the anabolic pathway to act as precursors of Body Protein Synthesis (BPS).
- NC = Nitrogen Catabolites is the percentage of released nitrogen waste and its equal to the percentage of amino acids following the catabolic pathway as well as to produce energy.

<table>
<thead>
<tr>
<th>Protein Type</th>
<th>NNU (%)</th>
<th>NC (%)</th>
<th>Glucose (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAP®</td>
<td>99%</td>
<td>1%</td>
<td>1%</td>
</tr>
<tr>
<td>Meat, Fish, Poultry</td>
<td>68%</td>
<td>32%</td>
<td>68%*</td>
</tr>
<tr>
<td>Soy, Whey, Casein, Milk</td>
<td>84%</td>
<td>16%</td>
<td>84%*</td>
</tr>
</tbody>
</table>

MAP®
... a Revolution in Protein Nutrition

* Average

---

dr. reinwald healthcare gmbh+co kg
Friedrich-Luber-Straße 29
DE 90592 Schwarzenbruck, Germany
Fon +49 (0)9128 73977-0
Fax +49 (0)9128 73977-29
Mail mail@dreinwald.com
Web www.dreinwald.com
Medullary Thyroid Cancer

Center for Personalized Cancer Therapeutics

DNA, RNA sequencing

modeling: Drosophila screening: robotics network analysis

mammalian testing

personalized therapy
Medullary Thyroid Cancer

Center for Personalized Cancer Therapeutics

A new, experimental approach to cancer, revolutionizing how we manage your disease.

Basic research tools developed by Mount Sinai scientists analyze your tumor.

Personalized therapies from genomics, network analysis, drosophila/mammal models, and robotics-based screening.

The result: novel treatments that select the most appropriate medication at doses tailored to you.

For more information:
Dr. Krzysztof Misiukiewicz, M.D.
Tisch Cancer Institute
212-659-5609
Krzysztof.Misiukiewicz@mssm.edu
8. International Charité-Mayo-Conference

Updates in Gynecology: A Global Perspective

15.–18. April 2015
Berlin

www.charite-mayo.de
Successes and Limitations of Targeted Cancer Therapy

Solange Peters
Rolf A. Stahel

VI + 118 p., 12 fig., 6 in color,
19 tab., 2014
CHF 163.00 / EUR 136.00 / USD 192.00
(hard cover)
Prices subject to change
EUR price for Germany, USD price for
USA and Latin America only

Your source for important clinical and translational
laboratory studies from around the world

Oncology

Editor-in-Chief
M. Markman

Associate Editor
P. Dufour Strasbourg

Regional Editor Japan
O. Hino Tokyo

More information at
www.karger.com/ocl
• Pay-per-View and Subscriber
  Access to Full Text
• Full Table of Contents
• Full Editorial Board
• Free Abstracts and Selected Articles
• Online Sample Issue
• Submission/Guidelines for
  Authors
• Subscription Details
• Free Alert Service
• Online Library Recommendation

Impact Factor: 2.613

Oncology
2014: Volumes 86, 87
6 issues per volume
Language: English
ISSN 0030–2414 (print)
ISSN 1423–0232 (online)

Listed in bibliographic services, including
Current Contents®/Life Sciences, MEDLINE,
Biological Abstracts, EMBASE/Excerpta
Medica

Karger
Join us in Phoenix, Arizona USA
visit isber.org for more information
leading since 1999

CONNECT GLOBALLY TO LEADING PROFESSIONALS IN BIOPRESERVATION. JOIN ISBER TODAY!

ORGANIZATIONAL MEMBERSHIP:
- Includes 2, 4, or 6 Individual Memberships
- Access to ISBER Best Practices for Biorepositories and Self-Assessment Tool (SAT)
- Product/service posting on ISBER MarketPlace
- Online subscription to Biopreservation and Biobanking – ISBER’s official journal
- Discounted exhibit space and registration rates for the ISBER Annual Meeting & Exhibits
- Advertising opportunities at a discounted rate
- Online jobs board at: www.biobankingjobs.com

INDIVIDUAL MEMBERSHIP:
- Access to ISBER Best Practices for Biorepositories and Self-Assessment Tool (SAT)
- Reduced registration rates for the ISBER Annual Meeting & Exhibits
- Online subscription to Biopreservation and Biobanking – ISBER’s official journal
- Online subscription to the ISBER Newsletter – the quarterly member e-newsletter
- Connect to a global group of professionals in biospecimen banking through the ISBER Members-only Forums
- Online jobs board at: www.biobankingjobs.com

www.isber.org
Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Special Offer to Conference Participants

Personal subscriptions to ANTICANCER RESEARCH (2015) and IN VIVO (2015) are offered at the special rate of EURO 200.00 (online) or EURO 300.00 (print & online) to all conference participants.

Subscription rates include all special issues and indexes, rapid DHL delivery and insurance. Subscriptions may be entered at the conference desk or throughout 2014 at the IIAR-Subscription Office.

anticancer research

International Journal of Cancer Research and Treatment

Volume 14, Number 1, January-February 2014

Contents

Editorial
Published by the International Institute of Anticancer Research

Book reviews

Author-Subject Indexes

Open access articles

Included in Pubmed and all abstracting and indexing services

Online with Stanford University HighWire Press

in vivo

International Journal of Experimental and Clinical Pathophysiology and Drug Research

Volume 10, Number 1, January-February 2014

Contents

Experimental Studies

Review

Conference abstracts

Author-Subject Indexes

Open access articles

Indexed in Pubmed and all major abstracting services

Online with Stanford University HighWire Press

Cancer genomics & proteomics

Published by the International Institute of Anticancer Research

Volume 1, Number 1, 2014

Contents

Research

Conference abstracts

Author-Subject Indexes

Open access articles

Indexed in Pubmed and all major abstracting services

Online with Stanford University HighWire Press

ANTICANCER RESEARCH is an independent international forum devoted to the rapid publication (print and online) of original high quality articles and reviews on all aspects of experimental and clinical oncology.

- 1981-2013
- 33 volumes
- over 108,100 pages
- over 16,000 original articles
- 769 reviews
- over 73,300 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes
- Open access articles
- Included in Pubmed and all abstracting and indexing services
- Online with Stanford University HighWire Press

IN VIVO is a multidisciplinary journal designed to bring together high quality original works and reviews on experimental and clinical biomedical research topics, including (a) experimental development and application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs; (c) development and characterization of models of biomedical research. A principal aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

- 1987-2013
- 27 volumes
- over 19,500 pages
- over 2,950 original articles and reviews
- over 21,400 authors
- Special issues
- Conference abstracts
- Author-Subject Indexes
- Open access articles
- Indexed in Pubmed and all major abstracting services
- Online with Stanford University HighWire Press

CANCER GENOMICS & PROTEOMICS (CGP) welcomes the submission of original high quality articles and reviews on the application of genomic and proteomic technology to basic, experimental and clinical cancer research.

The journals topical spectrum includes: (a) Molecular causes of carcinogenesis, cancer progression and metastasis; (b) Functional and structural aspects of genes in the cancer cell; (c) Advances in genomic and proteomic technologies applicable to cancer research; (d) Rational anticancer drug design and drug development.

CGP appears bimonthly online-only and open access with Stanford University HighWire Press.

All published articles are deposited in PubMed Central and indexed in all major bibliographic services.
Improvement of High-sensitivity Inflammation-based Glasgow Prognostic Score by Gastrectomy Is a Favorable Prognostic Factor in Patients with Gastric Cancer. S. TAKENO, T. HASHIMOTO, R. SHIBATA, K. MAKI, H. SHIWAKU, I. YAMANA, R. YAMASHITA, Y. YAMASHITA (Fukuoka, Japan) ................. 5695

A Prospective Case–Control Study on the Impact of Neoadjuvant Chemotherapy on Surgery-related Outcomes of Laparoscopic Radical Hysterectomy. G. BOGANI, A. CROMI, M. SERATI, E. DI NARO, J. CASARIN, N. MARCONI, D. STURLA, N. DONADELLO, F. GHEZZI (Varese; Bari, Italy) .............. 5703


Obesity is a Risk Factor for Multifocal Disease and Recurrence after Colorectal Cancer Surgery: A Case-Control Study. M. SCARPA, C. RUFFOLO, F. ERROI, A. FIOROT, S. BASATO, A. POZZA, F. CANAL, M. MASSANI, F. CAVALLIN, M. ANTONIUTTI, N. BASSI, C. CASTORO (Padova; Treviso, Italy) ................................................................. 5735

Results of S-1-based Chemotherapy for Platinum (and Antrathycline)-Refractory Advanced Thymic Carcinoma. F. HIRAI, T. SETO, E. INAMASU, G. TOYOKAWA, T. YOSHIDA, K. NOSAKI, T. TAKENAKA, M. YAMAGUCHI, M. TAKENYAMA, Y. ICHINOSE (Fukuoka, Japan) ................................................................. 5743

Prevalence of Human Papillomavirus Infection in Greek Patients with Squamous Cell Carcinoma of the Larynx. S. LASKARIS, I. SENGAS, P. MARAGODAKIS, E. TSIMPLAKI, E. ARGYRI, L. MANOLOPOULOS, E. PANOTOPOULOU (Piraeus; Athens, Greece) ........................................................................................................ 5749

Hypofractionated Stereotactic Radiotherapy Using CyberKnife as a Boost Treatment for Head and Neck Cancer, a Multi-institutional Survey: Impact of Planning Target Volume. H. YAMAZAKI, M. OGITA, K. HIMEI, S. NAKAMURA, K. YOSHIDA, T. KOTSUMA, Y. YAMADA, M. FUJIWARA, S. BAEK, Y. YOSHIOKA (Kyoto; Miyazaki; Okayama; Osaka, Japan) ........................................................................................................ 5755

ABSTRACTS OF THE NINTH INTERNATIONAL CONFERENCE OF ANTICANCER RESEARCH. October 6-10, 2014. Sithonia, Greece ........................................................................................................ 5761-6258
Neurofibromatosis Type 1 and GIST: Is There a Correlation? E. VALENCIA, M.W. SAIF (Boston, MA, USA) ........................................... 5609

Versican Expression in Tumor Epithelial Cells Is Correlated with a Good Prognosis in Gastric Cancer. N.S. KIM, H.H. LEE, C.-K. JUNG, H.M. JEON (Seoul, Republic of Korea) .............................................................................. 5613


Long-term Survival in Patients with Incurable Breast Cancer. An Analysis of 93 Cases. W. RHOMBERG, T. RHOMBERG (Feldkirch; Innsbruck, Austria) ................................................................................ 5637


Docetaxel and Intermittent Erlotinib in Patients with Metastatic Non-small Cell Lung Cancer: A Phase II Study From The Hellenic Cooperative Oncology Group. V. KARAVASILIS, P. KOSMIDIS, K.N. SYRIGOS, P. MAVROPOULOU, M.A. DIMOPOULOS, V. KOTOULA, D. PECTASIDES, I. BOUKOVINAS, G. KLOUVAS, A. KALOGERA-FOUNTZILA, C.N. PAPANDREOU, G. FOUNTZILAS, E. BRIASOULIS (Thessaloniki; Athens; Piraeus; Larissa; Ioannina, Greece) ...................................... 5649

Activity of a Three-drug Combination Including Cisplatin (CLOVER Regimen) for Poorly Differentiated Neuroendocrine Carcinoma. E. BAJETTA, L. CATENA, P. BIONDANI, S. PUSCEDDUI, M. VALENTE, N. BIANCO, E. NOVELLI (Monza; Milan; Grosseto; Novara, Italy) ........................................................................................................ 5657


The Self-Rating Score (SRS) Versus the Examiner Rating Score (ERS) in Measuring Helplessness in Healthy Individuals and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case–Control Study in Finland. M. ESOKELINEN, R. KORHONEN, T. SELANDER, P. OLLONEN (Kuopio, Finland) ........................................................................................................ 5677


Short-term Outcome of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy: Preliminary Analysis of a Multicentre Study. A. MACRÌ, V. ARCORACI, V. BELGRANO, M. CALDANA, T. CIOPPA, B. COSTANTINI, E. CUCINITTA, F. DE CIAN, P. DE IACO, G. DE MANZONI, A. DI GIORGIO, F. FLETES, F. MUFFATTI, E. ORSENIGO, A.D. PINNA, F. ROVIELLO, P. SAMMARTINO, G. SCAMBIA, E. SALADINO (Messina; Genoa; Verona; Siena; Rome; Bologna; Milan, Italy) ........................................................................................................ 5689
Clinical Studies


Intrapelvic Fat Makes Robot-assisted Radical Prostatectomy Difficult. Y. KADONO, S. UENO, T. MAKINO, M. OFUDE, K. IZUMI, T. GABATA, M. NAMIKI (Kanazawa, Japan) ................................ 5523


Features Related To Breast Cancer in an Entire Argentine Rural Population. L. CERMIGNANI, C. ALBERDI, S. DEMICHELIS, L. FERNÁNDEZ, M.M. MARTINUCCI, N. ZALAZAR, M. MÁRQUEZ, A. SEGAL-EIRAS, M.V. CROCE (La Plata; Lanús, Argentina; Stockholm, Sweden; Monterrey, NL, Mexico) ................ 5537

Impact of Comorbidity on Initial Treatment and Overall Survival in Elderly Head and Neck Cancer Patients. S. CHOKSHI, A. GHOBADI, M. ATHAR, S. SHAH, J. DOWELL (Dallas, TX, USA).......................... 5543

Maximal Debulking Liver Resection as a Beneficial Treatment Strategy for Advanced and Aggressive Colorectal Liver Metastases. K. TANAKA, T. MURAKAMI, Y. YABUSHITA, Y. HIROSHIMA, K. MATSUO, I. ENDO, K. KODA (Chiba; Yokohama, Japan) ............................................................................. 5547

Prognostic Significance of CD3+ Tumor-infiltrating Lymphocytes in Patients with Endometrial Carcinoma. P. ČERMÁKOVÁ, B. MELICHAR, M. TOMŠOVÁ, Z. ZOUL, H. KALÁBOVÁ, J. ŠPAČEK, M. DOLEŽEL (Hradec Králové; Olomouc, Czech Republic) .................................................................................. 5555

Role of Surgical Treatment in Breast Cancer Liver Metastases: A Single Center Experience. N. BACALBASA, S.O. DIMA, R. PURTAN-PURNICHESCU, V. HERLEA, I. POPEȘCU (Bucharest, Romania) .................... 5563


Beef Consumption and Fatty Acids Serum Concentration: Relationship with Salivary Gland Tumors in Córdoba, Argentina. M.C. CITTDININ, P.M. CORNAGLIA, N.R. PEROVIC, S. JOEKES, V.M. HEINZE, C. BERNAL, A.B. ACTIS (Córdoba; Martín; Santa Fe, Argentina).................................................. 5579

Concordance Between Biopsy and Radical Prostatectomy Specimen Gleason Score in Internal and External Pathology Facilities. A.A.C. GRASSO, G. COZZI, C. PALUMBO, G. ALBO, B. ROCCO (Milan, Italy) .... 5585

Identifying Melanoma Patients with 1-3 Brain Metastases Who May Benefit from Whole-brain Irradiation in Addition to Radiosurgery. S. HUTTENLOCHER, L. SEHMSICH, S.E. SCHILD, O. BLANK, D. HORNUNG, D. RADES (Lübeck; Güstrow; Hamburg, Germany; Scottsdale, AZ, USA) .......................................................... 5589

Protein Expression Differences Between Lung Adenocarcinoma and Squamous Cell Carcinoma with Brain Metastasis. K. FÁBIÁN, Z. NÉMETH, J. FURÁK, L. TISZLAVICZ, J. PÁPAY, T. KRENÁCS, J. TÍMÁR, J. MOLDVAY (Budapest; Szeged, Hungary) .......................................................... 5593


Contents continued on the preceding page
Quantitative Structure–Cytotoxicity Relationship of 3-Styrylchromones. C. SHIMADA, Y. UESAWA, R. ISHI-NOZAWA, M. ISHIHARA, H. KAGAYA, T. KANAMOTO, S. TERAKUBO, H. NAKASHIMA, K. TAKAO, Y. SUGITA, H. SAKAGAMI (Sakado, Saitama; Kiyose, Tokyo; Kanagawa, Japan) ... 5405

Crosstalk Between Tumor Blood Vessels Heterogeneity and Hormonal Profile of Pituitary Adenomas: Evidence and Controversies. B. BĂLINIŞTEANU, A.M. CIMPEAN, E. MELNIC, M. COCULESCU, R.A. CEAUŞU, M. RAICA (Timișoara; Bucharest, Romania; Chisinau, Moldova) ... 5413

Aberrations of BUBR1 and TP53 Gene Mutually Associated with Chromosomal Instability in Human Colorectal Cancer. Y. ZHAO, K. ANDO, E. OKI, A. IKAWA-YOSHIDA, S. IDA, Y. KIMURA, H. SAEKI, H. KITAO, M. MORITA, Y. MAEHARA (Fukuoka; Gotnemba, Japan; Shenyang, PR China) ... 5421

Impact of Sodium Butyrate on the Network of Adhesion/Growth-regulatory Galectins in Human Colon Cancer In Vitro. E.-M. KATZENMAIER, S. ANDRÉ, J. KOPITZ, H.-J. GABIUS (Heidelberg; Munich, Germany) ... 5429

Resveratrol Enhances Mitomycin C-mediated Suppression of Human Colorectal Cancer Cell Proliferation by Up-regulation of p21WAF1/CIP1. I. ALI, D.P. BRAUN (Zion, IL, USA) ... 5439

Selective Anticancer Activity of Neurotoxin 1-Methyl-4-Phenylpyridinium on Non-small Cell Lung Adenocarcinoma A549 Cells. R.B. BADISA, D.A. MINA, L.M. LATINWO, K.F.A. SOLIMAN (Tallahassee, FL, USA) ... 5447

Synergism from Combinations of tris(benzimidazole) monochloroplatinum(II) Chloride with Capsaicin, Quercetin, Curcumin and Cisplatin in Human Ovarian Cancer Cell Lines. L. ARZUMAN, P. BEALE, C. CHAN, J.Q. YU, F. HUQ (Lidcombe; Concord, NSW, Australia) ... 5453

Lysophosphatidylserine Stimulates Chemotactic Migration of Colorectal Cancer Cells Through GPR34 and PI3K/Akt Pathway. Y. IIDA, N.H.TSUNO, J. KISHIKAWA, K. KANEKO, K. MURONO, K. KAWAI, T. IKEDA, S. ISHIHARA, H. YAMAGUCHI, E. SUNAMI, J. KITAYAMA, Y. YATOMI, T. WATANABE (Tokyo, Japan) ... 5465

Synergistic Combinations of Tanshinone IIA and Trans-resveratrol Toward Cisplatin-comparable Cytotoxicity in HepG2 Human Hepatocellular Carcinoma Cells. T.-W. CHANG, C.-Y. LIN, Y.-J. TZENG, H.-S. LUR (Taipei; Hualien City, Taiwan, ROC) ... 5473


Gemtuzumab Ozogamicin and Olaparib Exert Synergistic Cytotoxicity in CD33-positive HL-60 Myeloid Leukemia Cells. T. YAMAUCHI, K. UZUI, R. NISHI, H. SHIGEMI, T. UEDA (Eiheiji, Fukui, Japan) ... 5487

Ouabain Mediates Integrin Switch in Human Lung Cancer Cells. C. NINSONTIA, P. CHANVORACHOTE (Bangkok, Thailand) ... 5495

Activating Mutations Affecting the NF-kappa B Pathway and EZH2-mediated Epigenetic Regulation are Rare Events in Primary Mediastinal Large B-cell Lymphoma. N. GEBAUER, T.T. HARDEL, J. GEBAUER, V. BERNARD, H. MERZ, A.C. FELLER, D. RADES, H. BIERSAKC, H. LEHNERT, C. THORNS (Luebeck, Germany) ... 5503

Inhibition of JNK Potentiates Temozolomide-induced Cytotoxicity in U87MG Glioblastoma Cells via Suppression of Akt Phosphorylation. V.A. VO, J.-W. LEE, H.J. LEE, W.J. CHUN, S.Y. LIM, S.-S. KIM (Chuncheon, Kangwon, Republic of Korea) ... 5509

Contents continued on the preceding page
Promise of Combining a Bcl-2 Family Inhibitor with Bortezomib or SAHA for Adult T-cell Leukemia/Lymphoma. N. KUNAMI, H. KATSUYA, R. NOGAMI, K. ISHITSUKA, K. TAMURA (Fukuoka, Japan) ............................................................................................................................ 5287

Differential Expression of VEGF and IL-1alpha After Photodynamic Treatment in Combination with Doxorubicin or Taxotere. D. DABKEVICIENE, A. SASNAUSKIENE, E. LEMAN, R. KVIETKAUSKAITE, V. KIRVELIENE (Vilnius, Lithuania; Haifa, Israel) .................................................................................... 5295

New Therapeutic Possibilities of Combined Treatment of Radiotherapy with Oxaliplatin and its Liposomal Formulation, Lipoxal™, in Rectal Cancer Using Xenograft in Nude Mice. T. TIPPAYAMONTRI, R. KOTB, L. SANCHE, B. PAQUETTE (Sherbrooke, QC; Victoria, BC, Canada) ................................................ 5303

The Apelin–APJ System Induces Tumor Arteriogenesis in Hepatocellular Carcinoma. J. MUTO, K. SHIRABE, T. YOSHIZUMI, T. IKEGAMI, S. AISHIMA, K. ISHIGAMI, Y. YONEMITSU, T. IKEDA, Y. SOEJIMA, Y. MAEHARA (Fukuoka, Japan) .................................................................................... 5313

Vasohibin-1 Increases the Malignant Potential of Colorectal Cancer and Is a Biomarker of Poor Prognosis. T. KITA JMIA, Y. TOIYAMA, K. TANAKA, S. SAIGUSA, M. KO BAYASHI, Y. INOUE, Y. MOHRI, M. KUSUNOKI (Ts u, Mie, Japan) ........................................................................................................ 5321


Synergistic Effects Between Catalase Inhibitors and Modulators of Nitric Oxide Metabolism on Tumor Cell Apoptosis. K. SCHEIT, G. BAUER (Freiburg, Germany) ........................................................................................................... 5337

Synchrotron-based Photon Activation Therapy Effect on Cisplatin Pre-treated Human Glioma Stem Cells. C. Ceresa, G. Nicolini, S. Semperboni, H. Requardt, G. Le Duc, C. Santini, M. Pellei, A. Bentivegna, L. Dalprà, G. Cavaletti, A. Bravin (Monza; Camerino, Italy; Grenoble, France) .................................................. 5351

Prognostic Significance of High Mobility Group Box 1 (HMGB1) Expression in Patients with Colorectal Cancer. M. Ueda, Y. Tahashi, Y. Shinden, S. Sakamura, H. Hirata, R. Uchi, H. Takano, J. Kurashige, T. Iuchi, H. Eguchi, K. Sugimachi, H. Yamamoto, Y. Doki, M. Mori, K. Mimori (Beppu; Suita, Osaka, Japan) ........................................................................................................... 5357

Resveratrol Augments Paclitaxel Treatment in MDA-MB-231 and Paclitaxel-resistant MDA-MB-231 Breast Cancer Cells. A.A. Sprouse, B.-S. Herbert (Indianapolis, IN, USA) .................................................. 5363

Effect of Wnt Inhibitors in Pancreatic Cancer. I. Wall, I.G.H. Schmidt-Wolf (Bonn, Germany) ............................................................ 5375

DNA Methylation at Selected CpG Sites in Peripheral Blood Leukocytes Is Predictive Of Gastric Cancer. A. Daukasa, A. Gulbinas, Z. Endzinas, J. Oldenburg, O. El-Maarrri (Kaunas, Lithuania; Bonn, Germany) ........................................................................................................... 5381


Contents continued on the preceding page